How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?

FMS-related tyrosine kinase 3 (FLT3) mutations, present in about 25%-30% of acute myeloid leukemia (AML) patients, constitute one of the most frequently detected mutations in these patients. The binding of FLT3L to FLT3 activates the phosphatidylinositol 3-kinase (PI3K) and RAS pathways, producing i...

Descripción completa

Detalles Bibliográficos
Autores principales: Perrone, Salvatore, Ottone, Tiziana, Zhdanovskaya, Nadezda, Molica, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344728/
https://www.ncbi.nlm.nih.gov/pubmed/37457126
http://dx.doi.org/10.20517/cdr.2022.130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344728/
https://www.ncbi.nlm.nih.gov/pubmed/37457126
http://dx.doi.org/10.20517/cdr.2022.130

Ejemplares similares